Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.48 |
| ▸ | KLK7 | P49862 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079109 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL4974304 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL2983027 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL496136 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL7438571 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL1104909 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL2983024 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| SCHEMBL639229 | 1.00 | ATM (0.54) | ATMCTSSCTSKCTSLCTSB | |
| Butylbenzyl SCHEMBL8490527 | 0.91 | CTSK (0.50) | ATMCTSSCTSKCTSLCTSB | |
| Butylbenzyl SCHEMBL8487457 | 0.91 | CTSK (0.50) | ATMCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220417-A1 | Processes for preparation of n-protected-beta-amino alcohols and n-protected-beta-amino epoxides | AJINOMOTO CO., INC. (JP) | 2004-11-04 | — | — | US | claimed |
| EP-1215209-B1 | Method for the production of a crystalline epoxide | AJINOMOTO KK (JP) | 2004-08-25 | — | — | EP | claimed |
| US-6764545-B2 | ADDING WATER TO A SOLUTION OF THE EPOXIDE CRYSTAL, (2R,3S) OR (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-1,2-EPOXY-4-PHENYLBUTANE IN A POLAR SOLVENT TO ALLOW CRYSTALLIZATION; COMPOUND IS AN HIV PROTEASE INHIBITOR INTERMEDIATE | AJINOMOTO CO., INC. (JP) | 2004-07-20 | — | — | US | claimed |
| EP-1346979-A1 | PROCESSES FOR PREPARATION OF N-PROTECTED- -AMINO ALCOHOLS AND N-PROTECTED- -AMINO EPOXIDES | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | claimed |
| US-20020087014-A1 | Production method of epoxide crystal | AJINOMOTO CO., INC. (JP) | 2002-07-04 | — | — | US | claimed |
| EP-1215209-A1 | Method for the production of a crystalline epoxide | Ajinomoto Co., Inc. (JP) | 2002-06-19 | — | — | EP | claimed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20020087014-A1 | Production method of epoxide crystal | AJINOMOTO CO., INC. (JP) | 2002-07-04 | — | — | US | disclosed |
| EP-1215209-A1 | Method for the production of a crystalline epoxide | Ajinomoto Co., Inc. (JP) | 2002-06-19 | — | — | EP | disclosed |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | DRAGOVICH PETER S (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331554-B1 | PICORNAVIRUS PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6020371-A | VIRICIDES; PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087014-A1 | Production method of epoxide crystal | EPHX2, PTGES3, EPHX1 | ATM 4683/4885CTSS 4308/4885CTSK 3995/4885 |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | RNASEL, RNASE1, GTF3C3 | ATM 4561/4885CTSS 110/4885CTSK 390/4885 |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, DARS1, CYP3A43 | ATM 4028/4885CTSS 335/4885CTSK 709/4885 |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | ATM 4408/4885CTSS 675/4885CTSK 1554/4885 |
| US-20040220417-A1 | Processes for preparation of n-protected-beta-amino alcohols and n-protected-beta-amino epoxides | NPEPPS, DNPEP, ANPEP | ATM 3659/4885CTSS 463/4885CTSK 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.